07. Role of surgery in management of TB: a promise or redundancy?

Friday, 04 December 2015, 10:30 - 12:00
Room Da Gama/Diaz-Westin

Type of session
Symposium

Track
Drug-resistant TB care and treatment, including trials

Track2 (optional)
Patient-centred care

Description
Drug-resistant TB (DR-TB) is a serious public health concern in a number of countries and causes the resurgence of barely curable cases. There are only a few therapeutic options available in these cases and the supply of new anti-TB drugs and regimens is very limited. Surgery has been applied as adjunct to medical treatment for drug resistant TB as well as in some cases of extra-pulmonary TB. The effectiveness of surgery in these situations is not well evaluated and its role is poorly established while indications for surgery and the surgical practices themselves vary across countries.

Target audience
1. National TB and HIV programmes
2. TB technical organizations
3. International donors

Objectives
1. To review current policies and practices of surgical interventions in pulmonary DR-TB and extrapulmonary TB
2. To present available evidence on the role of surgery in management of TB
3. To discuss the role of surgery and its main indications and prerequisites

Keywords
TB; treatment of DR-TB; surgery

Coordinator(s)
Fuad Mirzayev (Switzerland), Colleen Acosta (Denmark)

Chair(s)
Fuad Mirzayev (Switzerland)

Presentations
10:30 - 10:40 Experience from India: main indications and realities of thoracic surgery in TB patients
Ravindra Kumar Dewan (India)

10:45 - 10:55 Should we operate on patients with persistent cavities at the end of TB treatment?
Jean-Pierre Zellweger (Switzerland)

11:00 - 11:10 Experience from the Russian Federation: main risks and benefits of surgical interventions in TB
Denis Krasnov (Russian Federation)

11:15 - 11:25 When should surgical treatment of TB be considered?
Alfred Lardizabal (USA)

11:30 - 11:40 Will new drugs and regimens make surgical treatment of TB unnecessary?
GB Migliori (Italy)

11:45 - 12:00 Discussion